Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Breast Neoplasms: HELP
Marco Angelo Colleoni
Based on 122 articles published since 2007
||||
Expertise Level
The expertise of Marco Angelo Colleoni ranks in the
  • Top 0.022%
  • ... of 253,558 published authors worldwide on Breast Neoplasms
  • ... from 2007 through 2018
  • ... based on contributions to 122 articles on the topic.
Graphical view (beta)
Uncounted papers?
Get your prestigious
Expert badge
similar to this:
 
Aliases Colleoni, M   ·   Colleoni, Marco   ·   Colleoni, Marco Angelo
Work Locations
Details
Most likely:    European Institute of Oncology      
2017
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Pubmed 28093280
  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston. · International Breast Cancer Study Group Statistical Center, Boston, USA. · University of Calgary and Canadian Cancer Trials Group, Calgary, Canada. · Division of Cancer Medicine, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne. · Australia & New Zealand Breast Cancer Trials Group and International Breast Cancer Study Group, Melbourne, Australia. · The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, USA. · National Institute of Oncology and International Breast Cancer Study Group, Medical Oncology, Budapest, Hungary. · Division of Medicine, Instituto Nacional de Enfermedades Neoplásicas and International Breast Cancer Study Group, Lima, Peru. · Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan. · Medical Oncology, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo. · Medical Oncology, ASST Sette Laghi-Ospedale di Circolo and Fondazione Macchi and International Breast Cancer Study Group, Varese, Italy. · Allan Blair Cancer Center, Regina, Canada. · Medical Oncology, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano, Italy. · Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre and International Breast Cancer Study Group, Mumbai, India. · Breast Center St. Gallen, Swiss Group for Clinical Cancer Research (SAKK), St. Gallen. · International Breast Cancer Study Group, St. Gallen, Switzerland. · Australia & New Zealand Breast Cancer Trials Group and International Breast Cancer Study Group, The Tweed Hospital, Griffith University Gold Coast, Tweed Heads, Australia. · Harvard T.H. Chan School of Public Health, Frontier Science and Technology Research Foundation, Boston, USA. · International Breast Cancer Study Group and University of Sydney, Sydney, Australia. · European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · Oncology Institute of Southern Switzerland, Swiss Group for Clinical Cancer Research (SAKK), Bellinzona. · International Breast Cancer Study Group, Lugano, Viganello, Switzerland. · Pubmed 28911092
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. Electronic address: · Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy; University of Milan, School of Medicine, Italy. Electronic address: · Pubmed 28544923
  • Division of Medical Senology, European Institute of Oncology, 20141 Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, 20141 Milan, Italy. · Division of Early Drugs Development, European Institute of Oncology, 20141 Milan, Italy. · Palliative Care, Sassari, Italy. · Department of Medicine, European Institute of Oncology, 20141 Milan, Italy. · Division of Medical Senology, European Institute of Oncology, 20141 Milan, Italy. Electronic address: · Pubmed 28131905
  • Breast Cancer Program, Istituto Europeo di Oncologia, Milano, Italy. · Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. · Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. · Klinik St. Anna, Luzern, Switzerland. · German Breast Group, Neu-Isenburg, Germany. · Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. · Department of Medical Oncology, Institut Jules Bordet, UniversitÕ Libre de Bruxelles, Brussels, Belgium. · Tumor and Breast Center ZeTuP, St. Gallen. · Breast Center, Kantonsspital St. Gallen, St. Gallen, Switzerland. · Institut de Cancérologie Gustave Roussy, Villejuif, France. · Memorial Sloan Kettering Cancer Center, New York, USA. · Karolinska Institute and University Hospital, Stockholm, Sweden. · University of Bordeaux, Bordeaux, France. · Universitäts-Frauenklinik Tübingen, Tübingen, Germany. · Champalimaud Cancer Centre, Lisbon, Portugal. · Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. · Institut für Pathologie, Charité Universitätsmedizin Berlin, Berlin, Germany. · Azienda Usl Toscana Centro, Prato, Italy. · Rigshospitalet, Copenhagen, Denmark. · Peter McCallum Cancer Centre, Melbourne, Australia. · Marmara University School of Medicine, Istanbul, Turkey. · University of Toronto, Mount Sinai Hospital, Toronto, Canada. · University of Munich, München, Germany. · Comprehensive Cancer Center, University of Michigan, Ann-Arbor, USA. · National Taiwan University Hospital, Taipei, Taiwan. · University of Ulm, Ulm, Germany. · The National Cancer Institute, Cairo University, Cairo, Egypt. · Medical University of Gdansk, Gdansk, Poland. · Hospital Affiliated to Military Medical Science, Beijing, China. · Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrensky University Hospital, Gothenburg, Sweden. · Baylor College of Medicine, Houston, USA. · Institute of Oncology Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland. · Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Canada. · National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea. · Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. · LKH Salzburg, Paracelsus Medical University Clinics, Salzburg, Austria. · N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation. · Fudan University Cancer Hospital, Shanghai, China. · The Royal Marsden, Sutton, Surrey, UK. · Graduate School of Medicine Kyoto University, Sakyo-ku, Kyoto City, Japan. · Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. · University of Milan, Milan. · Istituto Europeo di Oncologia, Milan, Italy. · Hamamatsu Oncology Center, Hamamatsu, Japan. · McMaster University, Hamilton, Canada. · National Cancer Center, Chaoyang District, Beijing, China. · Pubmed 28838210
  • Department of Surgery and Cancer, Imperial College London, London, UK. · Department of Experimental Oncology, European Institute of Oncology Milan, Italy. · Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, IT. · Swammerdam Institute for Life Sciences, University of Amsterdam. · Genomics Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA, USA. · Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), Italy. · Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), and Institute for Stem Cell Technology and Experimental Medicine GmbH, Heidelberg, Germany. · Division of Pathology, European Institute of Oncology and University of Milan, School of Medicine, Milan, Italy. · Department of Oncology and Hemato-oncology, University of Milano, Milan, IT. · Division of Medical Senology, European Institute of Oncology, IEO, Milan, Italy. · Department of Biosciences, University of Milano, Milan, IT. · Pubmed 28112739
  • Division of Breast Surgery, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Breast Surgery, European Institute of Oncology, Milan, Italy. · Division of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy. · Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Milan, Italy. · Division of Pathology, European Institute of Oncology, Milan, Italy; University of Milan, School of Medicine, Milan, Italy. · Division of Breast Surgery, European Institute of Oncology, Milan, Italy; University of Milan, School of Medicine, Milan, Italy. · Pubmed 27810700
2016
  • IBCSG Central Pathology Laboratory, Department of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · University of Milan, Milan, Italy. · International Breast Cancer Study Group (IBCSG) Statistical Center, Boston, MA, USA. · Harvard T. H. Chan School of Public Health, Boston, MA, USA. · IBCSG Central Pathology Laboratory, Department of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · University of Milan, Milan, Italy. · Division of Experimental Therapeutics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · National Institute of Oncology, Ráth György u. 7/9, Budapest, 1122, Hungary. · Breast Center St. Gallen, Kantonsspital, St. Gallen, Switzerland. · Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. · Divisione di Oncologia, Ospedale degli Infermi, Viale Settembrini 2, 47923, Rimini, Italy. · Program for Breast Health, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · International Breast Cancer Study Group, Translational Research Coordination and Central Pathology Office, IBCSG Coordinating Center, Effingerstrasse 40, 3008, Bern, Switzerland. · Frontier Science and Technology Research Foundation, Boston, MA, USA. · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. · Harvard Medical School, Boston, MA, USA. · Pubmed 27372069
  • University of Calgary, Alberta, Canada · Pfizer Inc., Collegeville, Pennsylvania, USA. · Pfizer Inc., New York, New York, USA. · University of Pennsylvania, Philadelphia, Pennsylvania, USA. · Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. · National Cancer Center, Goyang-si, Republic of Korea. · Istituto Europeo di Oncologia, Milan, Italy. · Aichi Cancer Center Hospital, Nagoya, Japan. · Brustzentrum der Universität München, Munich, Germany. · Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, Illinois, USA. · Pfizer Inc., San Diego, California, USA. · Pfizer Inc., Cambridge, Massachusetts, USA. · Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom. · University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA. · Pubmed 27368881
  • Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL, USA. Electronic address: · Institute of Cancer Research and Royal Marsden Hospital, London, UK. · Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital #4, Dnipropetrovsk, Ukraine. · National Cancer Center, Goyang-si, South Korea. · Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. · NHO Osaka National Hospital, Osaka, Japan. · Istituto Europeo di Oncologia, Milan, Italy. · Center for Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA. · Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. · Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. · Aichi Cancer Center Hospital, Nagoya, Japan. · Brustzentrum der Universität München (LMU), Munich, Germany. · Pfizer, San Diego, CA, USA. · Pfizer, Cambridge, MA, USA. · Pfizer, Collegeville, PA, USA. · Pfizer, New York, NY, USA. · University of California, Los Angeles, Los Angeles, CA, USA. · Pubmed 26947331
  • Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy. · International Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, 450 Brookline Avenue, Boston, MA, 02215, USA. · Institute of Oncology of Southern Switzerland (IOSI), Bellinzona, Switzerland. · International Breast Cancer Study Group, Bern, Switzerland. · Swiss Group for Clinical Cancer Research SAKK, Lugano Viganello, Switzerland. · IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA. · Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Via Ripamonti 435, Milan, 20141, Italy. · Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy. · International Breast Cancer Study Group (IBCSG) Coordinating Center, Effingerstrasse 40, Bern, CH-3008, Switzerland. · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy. · IBCSG Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA. · Dana-Farber Cancer Institute, Department of Biostatistics and Computatonal Biology, 450 Brookline Ave, Boston, MA, 02215, USA. · International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, Australia. · IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, 450 Brookline Avenue, Boston, MA, 02215, USA. · Program for Breast Health, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy. · Translational Research Coordination and Central Pathology Office, IBCSG Coordinating Center, Effingerstrasse 40, Bern, CH-3008, Switzerland. · Breast Unit of Southern Switzerland, Bellinzona, Switzerland. · National Cancer Institute of Canada, Kingston, ON, Canada. · Pubmed 27825388
  • Department of Oncology, Institute of Clinical Sciences, Sahgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: · Department of Mathematics and Statistics, University of Vermont, Burlington, Vermont. · International Breast Cancer Study Group Statistical Center, Frontier Science and Technology Research Foundation, Boston, Massachusetts. · International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Harvard T. F. Chan School of Public Health, Boston, Massachusetts. · International Breast Cancer Study Group and University of Sydney, Sydney, Australia. · Senior Consultant Breast Cancer, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · International Breast Cancer Study Group, Bern, Switzerland. · Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · Institute of Radiotherapy, Klinik Hirslanden, Zürich, Switzerland. · Pubmed 27598802
  • Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan 20141, Italy. Electronic address: · Pubmed 26869050
  • Department of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy. · Department of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy. · Division of Radiotherapy, European Institute of Oncology, Milan, Italy. · Department of Surgery, European Institute of Oncology, Milan, Italy. · Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 26842491
  • Division of Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Division of Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Department of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy; University of Milan, School of Medicine, Milan, Italy. · Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 26746091
2015
  • Division of Medical Senology and International Breast Cancer Study Group, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 26241939
  • Division of Medical Senology, and International Breast Cancer Study Group, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy, · Pubmed 26177891
  • International Breast Cancer Study Group Coordinating Center and Bern University Hospital, Inselspital, Bern, Switzerland. Electronic address: · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA. · International Breast Cancer Study Group Coordinating Center, Bern, Switzerland. · Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · Dana-Farber Cancer Institute and Alliance for Clinical Trials in Oncology, Boston, MA, USA. · Medical Oncology, Osp Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo, Italy. · Medical Oncology, Ospedale di Circolo and Fondazione Macchi, and International Breast Cancer Study Group, Varese, Italy. · Medical Oncology, Centro di Riferimento Oncologico, and International Breast Cancer Study Group, Aviano, Italy. · Breast Center, Kantonsspital St Gallen, Swiss Group for Clinical Cancer Research (SAKK), and International Breast Cancer Study Group, St Gallen, Switzerland. · Department of Oncology, University Hospital of Udine, University of Udine and International Breast Cancer Study Group, Udine, Italy. · Oncology Unit, Salvatore Maugeri Foundation, and International Breast Cancer Study Group, Pavia, Italy. · Surgical Oncology, Breast Services, Tata Memorial Hospital, and International Breast Cancer Study Group, Mumbai, India. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Institute of Oncology of Southern Switzerland, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, Lugano Viganello, Switzerland. · University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL, USA. · Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne and Australia and New Zealand Breast Cancer Trials Group, Newcastle, NSW, Australia, and International Breast Cancer Study Group. · International Breast Cancer Study Group Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA. · International Breast Cancer Study Group and University of Sydney, Sydney, NSW, Australia. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Frontier Science and Technology Research Foundation, Boston, MA, USA. · Program for Breast Health (Senology), European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland. · Tom Baker Cancer Centre and National Cancer Institute of Canada Clinical Trials Group, Calgary, AB, Canada. · Pubmed 26092816
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, and Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Department of Pathology, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine, Milan, Italy. · Department of Pathology, European Institute of Oncology, Milan, Italy. · University of Milan School of Medicine, Milan, Italy; Division of Senology, European Institute of Oncology, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Program of Senology (Breast Health), European Institute of Oncology, Milan, Italy. · Pubmed 25933934
  • Department of Biostatistics and Computational Biology, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Mailstop CLS-11007, Boston, MA, 02215, USA. · Institute of Oncology of Southern Switzerland, Swiss Group for Clinical Cancer Research (SAKK), Lugano Viganello, Switzerland. · Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia. · Australia & New Zealand Breast Cancer Trials Group (ANZBCTG), University of Newcastle, Callaghan, NSW, Australia. · The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL, USA. · Tom Baker Cancer Centre and NCIC Clinical Trials Group, Calgary, AB, Canada. · International Breast Cancer Study Group Coordinating Center and Central Pathology Office, Bern, Switzerland. · International Breast Cancer Study Group Central Pathology Office, Department of Pathology, European Institute of Oncology, Milan, Italy. · International Breast Cancer Study Group Central Pathology Office, Department of Pathology, European Institute of Oncology, Milan, Italy. · Pathological Department, National Institute of Oncology, Budapest, Hungary. · Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. · Division of Pathology, Salvatore Maugeri Foundation, Pavia, Italy. · Struttura Operativa Complessa di Anatomia Patologica, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy. · Kantonsspital St. Gallen, Swiss Group for Clinical Cancer Research (SAKK), St. Gallen, Switzerland. · University of Insubria-Ospedale di Circolo and Fondazione Macchi, Varese, Italy. · Department of Pathology, Vall d'Hebron University Hospital, SOLTI Group, Barcelona, Spain. · Pathology Department, Hospital Universitario «12 de Octubre», i+12, Universidad Complutense Madrid, SOLTI Group, Madrid, Spain. · Laboratoire Anatomopathologie, Institut Bergonié, Bordeaux, France. · EORTC, Brussels, Belgium. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Program for Breast Health, European Institute of Oncology, Milan, Italy. · International Breast Cancer Study Group Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA. · University of Sydney, Sydney, Australia. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Harvard T.H. Chan School of Public Health, Boston, MA, USA. · Frontier Science and Technology Research Foundation, Boston, MA, USA. · International Breast Cancer Study Group Central Pathology Office, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 26493064
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy · Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA. · Institute of Cancer Sciences, Glasgow University, Glasgow. · Southern General Hospital, Glasgow, UK. · Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan, Italy. · Breast Center, Kantonsspital, St Gallen Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. · Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark. · Department of Pathology, Institut Bergonié, Bordeaux. · Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier, France. · Department of Pathology, Rigshospitalet, Copenhagen, Denmark. · International Breast Cancer Study Group (IBCSG) Statistical Center. · Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, Boston, USA. · International Breast Cancer Study Group, Bern, Switzerland University of Sydney, Sydney, Australia. · Program of Breast Health, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 26387144
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Laboratory Medicine, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Department of Medicine, European Institute of Oncology, Milan, Italy. · Division of Pathology, European Institute of Oncology, Milan, Italy; School of Medicine, University of Milan, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Pubmed 26362840
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Department of Quantitative Methods and Statistics, University of Milan-Bicocca, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Department of Pathology, European Institute of Oncology, Milan, Italy; School of Medicine, University of Milan, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Department of Pathology, European Institute of Oncology, Milan, Italy. · Program of Senology (Breast Health), European Institute of Oncology, Milan, Italy. · Pubmed 26255932
  • Division of Medical Senology, European Institute of Oncology, Milan · Department of Quantitative Methods and Statistics, University of Milan-Bicocca, Milan Division of Epidemiology and Biostatistics. · Department of Pathology, European Institute of Oncology, Milan School of Medicine, University of Milan, Milan. · Division of Epidemiology and Biostatistics. · Division of Medical Senology, European Institute of Oncology, Milan. · Division of Senology. · Department of Pathology, European Institute of Oncology, Milan. · Program of Senology (Breast Health), European Institute of Oncology, Milan, Italy. · Pubmed 25411418
2014
  • International Breast Cancer Study Group; European Institute of Oncology, Milan, Italy. · Pubmed 24516011
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 24998489
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Prevention and Genetics, European Institute of Oncology, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Scientific Direction, European Institute of Oncology, Milan, Italy. · Pubmed 24742826
  • Division of Pathology, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Pathology, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Pathology, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. Electronic address: · Pubmed 24709436
  • International Breast Cancer Study Group and Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. Electronic address: · International Breast Cancer Study Group and Breast Health Program, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 24360786
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, Unit of Biostatistics, Epidemiology and Public Health, University of Milan-Bicocca, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; School of Medicine, University of Milan, Italy. · School of Medicine, University of Milan, Italy; Molecular Senology Unit, European Institute of Oncology, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy. · Vice-Scientific Director, European Institute of Oncology, Milan, Italy. · Pubmed 24325948
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, Italy. · Integrated Breast Surgery Unit, European Institute of Oncology and University of Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Division of Radiation Oncology, European Institute of Oncology, Milan, Italy. · Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 24183613
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Gynecologic Oncology, European Institute of Oncology, Milan, Italy. · Division of Diagnostic Radiology, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 24529906
2013
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Pubmed 24074780
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 23633450
2012
  • Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22039080
  • Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 22987970
2011
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22015285
  • European Institute of Oncology, Milan, Italy. · Pubmed 21321298
2010
  • Research Unit, Medical Senology and International Breast Cancer Study Group, European Institute of Oncology, Milan, Italy. · Pubmed 20943602
  • Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 20471822
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Università degli Studi di Milano, Milan, Italy. · Pubmed 20458051
2009
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy. · Pubmed 19914533
  • Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 19468030
  • Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Milan, Italy. · Pubmed 19218304
2017
  • Signe Borgquist and Judy E. Garber, Dana-Farber Cancer Institute, Harvard Medical School; Anita Giobbie-Hurder, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute; Richard D. Gelber, IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, T.H. Chan Harvard School of Public Health, and Frontier Science and Technology Research Foundation; Karen N. Price, IBCSG Statistical Center and Frontier Science and Technology Research Foundation; Meredith M. Regan, IBCSG Statistical Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA; Signe Borgquist, Lund University, Lund, Sweden; Thomas P. Ahern, University of Vermont, Burlington, VT; Marco Colleoni and Aron Goldhirsch, IBCSG and European Institute of Oncology, Milan, Italy; István Láng, IBCSG and National Institute of Oncology, Budapest, Hungary; Marc Debled, Institut Bergonié, Bordeaux, France; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Roger von Moos, Cantonal Hospital Graubuenden, Chur; Swiss Group for Clinical Cancer Research and IBCSG; Manuela Rabaglio, IBCSG Coordinating Center and Inselspital, Bern; Beat Thürlimann, Breast Center St. Gallen, Kantonsspital, St. Gallen; Swiss Group for Clinical Cancer Research and IBCSG, Bern, Switzerland; Ian Smith, The Royal Marsden Hospital, London, United Kingdom; and Alan S. Coates, IBCSG and University of Sydney School of Public Health, Sydney, Australia. · Pubmed 28380313
  • Poornima Saha and Gini F. Fleming, The University of Chicago Medical Center, Chicago, IL; Meredith M. Regan, Weixiu Luo, Harold J. Burstein, and Richard D. Gelber, Dana-Farber Cancer Institute; Meredith M. Regan, Harold J. Burstein, and Richard D. Gelber, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello; Karin Ribi and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern, Switzerland; Prudence A. Francis, Peter MacCallum Cancer Center; St Vincent's Hospital; University of Melbourne, Melbourne; Josephine Stewart, Austin and Heidelberg Repatriation Medical Center, Heidelberg, Victoria; Prudence A. Francis, Josephine Stewart, and Michelle Nottage, University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, New South Wales; Michelle Nottage, Royal Brisbane Hospital, Brisbane, Queensland, Australia; Barbara A. Walley, University of Calgary; National Cancer Institute of Canada, Calgary, Alberta, Canada; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Vani Parmar, Tata Memorial Centre, Mumbai, India; Roberto Torres, Instituto Nacional del Cancer, Santiago de Chile, Chile; Meritxell Bellet, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona, Barcelona; Antonia Perelló, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Faysal Dane, Marmara University Hospital, Istanbul, Turkey; Antonio Moreira, Instituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugal; Daniel Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa; and Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy. · Pubmed 28654365
2016
  • Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania. · Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania. · Pubmed 27325862
  • Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H. Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria, Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland; Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven, Belgium; István Láng, National Institute of Oncology, Budapest, Hungary. · Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H. Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria, Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland; Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven, Belgium; István Láng, National Institute of Oncology, Budapest, Hungary. · Pubmed 27217455
  • Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru. · Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru. · Pubmed 27044936
  • Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland. · Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland. · Pubmed 26786933
2015
  • Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia. · Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia. · Pubmed 26215945
  • Division of Breast Surgery, European Institute of Oncology, Milan, Italy, · Pubmed 25515197
2014
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy, · Pubmed 25007961
2013
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy. · Pubmed 23915740
  • Department of Medicine, European Institute of Oncology, Milan, Italy. Electronic address: · Pubmed 23871531
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Pubmed 23725877
  • Molecular Senology Unit, Senology Division, European Institute of Oncology, Milan, Italy. · Pubmed 23491275
  • Division of Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Pubmed 24091127
  • Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Pubmed 23912960
  • Division of Pathology, European Institute of Oncology, Milan, Italy. · Pubmed 23763700
  • Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy. · Pubmed 23748238
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 23245877
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 23098574
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan 20141, Italy. · Pubmed 23022996
2012
  • European Institute of Oncology, Medical Oncology, Milan, Italy. · Pubmed 22827581
  • Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22520733
  • Medical Senology Research Unit & Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22749924
  • Division of Breast Surgery, European Institute of Oncology, Milan, Italy. · Pubmed 22618719
  • Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 22467243
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22399188
  • Medical Senology Research Unit, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22341133
  • Division of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 22228432
  • Division of Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 22065291
  • Department of Medicine, Division of Medical Oncology, Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 21525402
  • Division of Senology, Unit of Molecular Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 21468637
2011
  • Division ofSenology, European Institute of Oncology, Milan, Italy. · Pubmed 22015302
  • Division of Senology, European Institute of Oncology, Milano, Italy. · Pubmed 21479691
  • International Breast Cancer Study Group Central Pathology Office, Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 21335417
  • Division of Breast Surgery, European Institute of Oncology, Milan, Italy. · Pubmed 22015303
  • Division of Medical Oncology, Department of Medicine, Unit Research of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 21822638
  • Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 21452022
  • Medical Senology Research Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 21397505
  • Division of Senology, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 21248632
  • Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, Milano, Italy. · Pubmed 21221766
  • Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435, Milan, Italy. · Pubmed 20638282
2010
  • Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 20304562
  • European Institute of Oncology, Medical Senology Research Unit, Division of Medical Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 20095792
  • Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 21147693
  • Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 20533032
  • Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 20625816
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 20332136
  • Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 20117001
  • Division of Breast Surgery, European Institute of Oncology, Via Ripamonti 435, Milan, Italy. · Pubmed 19944605
  • Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 19633051
2009
  • Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 20044624
  • Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano, Italy. · Pubmed 19884553
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 19562480
  • Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy. · Pubmed 19264824
  • Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 19182679
Probable:    Miscellaneous cities in Italy      
2015
  • Division of Medical Senology, European Institute of Oncology, Italy; International Breast Cancer Study Group, Italy. Electronic address: · Division of Medical Senology, European Institute of Oncology, Italy. · Pubmed 26249119
Probable:    University of Milan Statale      
2010
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Università degli Studi di Milano, Milan, Italy. · Pubmed 20458051
2017
  • Signe Borgquist and Judy E. Garber, Dana-Farber Cancer Institute, Harvard Medical School; Anita Giobbie-Hurder, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute; Richard D. Gelber, IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, T.H. Chan Harvard School of Public Health, and Frontier Science and Technology Research Foundation; Karen N. Price, IBCSG Statistical Center and Frontier Science and Technology Research Foundation; Meredith M. Regan, IBCSG Statistical Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA; Signe Borgquist, Lund University, Lund, Sweden; Thomas P. Ahern, University of Vermont, Burlington, VT; Marco Colleoni and Aron Goldhirsch, IBCSG and European Institute of Oncology, Milan, Italy; István Láng, IBCSG and National Institute of Oncology, Budapest, Hungary; Marc Debled, Institut Bergonié, Bordeaux, France; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Roger von Moos, Cantonal Hospital Graubuenden, Chur; Swiss Group for Clinical Cancer Research and IBCSG; Manuela Rabaglio, IBCSG Coordinating Center and Inselspital, Bern; Beat Thürlimann, Breast Center St. Gallen, Kantonsspital, St. Gallen; Swiss Group for Clinical Cancer Research and IBCSG, Bern, Switzerland; Ian Smith, The Royal Marsden Hospital, London, United Kingdom; and Alan S. Coates, IBCSG and University of Sydney School of Public Health, Sydney, Australia. · Pubmed 28380313
  • Poornima Saha and Gini F. Fleming, The University of Chicago Medical Center, Chicago, IL; Meredith M. Regan, Weixiu Luo, Harold J. Burstein, and Richard D. Gelber, Dana-Farber Cancer Institute; Meredith M. Regan, Harold J. Burstein, and Richard D. Gelber, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello; Karin Ribi and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern, Switzerland; Prudence A. Francis, Peter MacCallum Cancer Center; St Vincent's Hospital; University of Melbourne, Melbourne; Josephine Stewart, Austin and Heidelberg Repatriation Medical Center, Heidelberg, Victoria; Prudence A. Francis, Josephine Stewart, and Michelle Nottage, University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, New South Wales; Michelle Nottage, Royal Brisbane Hospital, Brisbane, Queensland, Australia; Barbara A. Walley, University of Calgary; National Cancer Institute of Canada, Calgary, Alberta, Canada; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Vani Parmar, Tata Memorial Centre, Mumbai, India; Roberto Torres, Instituto Nacional del Cancer, Santiago de Chile, Chile; Meritxell Bellet, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona, Barcelona; Antonia Perelló, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Faysal Dane, Marmara University Hospital, Istanbul, Turkey; Antonio Moreira, Instituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugal; Daniel Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa; and Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy. · Pubmed 28654365
2016
  • Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania. · Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania. · Pubmed 27325862
  • Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H. Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria, Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland; Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven, Belgium; István Láng, National Institute of Oncology, Budapest, Hungary. · Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H. Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria, Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland; Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven, Belgium; István Láng, National Institute of Oncology, Budapest, Hungary. · Pubmed 27217455
  • Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru. · Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru. · Pubmed 27044936
  • Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland. · Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland. · Pubmed 26786933
2015
  • Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia. · Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia. · Pubmed 26215945
2013
  • Division of Pathology, European Institute of Oncology, Milan, Italy. · Pubmed 23763700
2011
  • International Breast Cancer Study Group Central Pathology Office, Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 21335417
  • Division of Senology, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 21248632
2010
  • Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 19633051
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 122 total) written by Marco Angelo Colleoni about Breast Neoplasms:

  • Metronomics in the neoadjuvant and adjuvant treatment of breast cancer. 2017
  • Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. 2017
  • Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. 2017
  • Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. 2017
  • Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. 2017
  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. 2017
  • Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. 2017
  • Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer. 2017
  • Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. 2017
  • Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. 2016
Show List of Full Article Records
Google Searches

Learn more about Marco Angelo Colleoni using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
European Institute of Oncology
Miscellaneous cities in Italy
University of Milan Statale
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
European Institute of Oncology
2017
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Pubmed 28093280
  • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston. · International Breast Cancer Study Group Statistical Center, Boston, USA. · University of Calgary and Canadian Cancer Trials Group, Calgary, Canada. · Division of Cancer Medicine, Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne. · Australia & New Zealand Breast Cancer Trials Group and International Breast Cancer Study Group, Melbourne, Australia. · The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, USA. · National Institute of Oncology and International Breast Cancer Study Group, Medical Oncology, Budapest, Hungary. · Division of Medicine, Instituto Nacional de Enfermedades Neoplásicas and International Breast Cancer Study Group, Lima, Peru. · Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan. · Medical Oncology, Ospedale Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo. · Medical Oncology, ASST Sette Laghi-Ospedale di Circolo and Fondazione Macchi and International Breast Cancer Study Group, Varese, Italy. · Allan Blair Cancer Center, Regina, Canada. · Medical Oncology, Centro di Riferimento Oncologico and International Breast Cancer Study Group, Aviano, Italy. · Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre and International Breast Cancer Study Group, Mumbai, India. · Breast Center St. Gallen, Swiss Group for Clinical Cancer Research (SAKK), St. Gallen. · International Breast Cancer Study Group, St. Gallen, Switzerland. · Australia & New Zealand Breast Cancer Trials Group and International Breast Cancer Study Group, The Tweed Hospital, Griffith University Gold Coast, Tweed Heads, Australia. · Harvard T.H. Chan School of Public Health, Frontier Science and Technology Research Foundation, Boston, USA. · International Breast Cancer Study Group and University of Sydney, Sydney, Australia. · European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · Oncology Institute of Southern Switzerland, Swiss Group for Clinical Cancer Research (SAKK), Bellinzona. · International Breast Cancer Study Group, Lugano, Viganello, Switzerland. · Pubmed 28911092
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. Electronic address: · Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Biobank for Translational Medicine Unit, Department of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy; University of Milan, School of Medicine, Italy. Electronic address: · Pubmed 28544923
  • Division of Medical Senology, European Institute of Oncology, 20141 Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, 20141 Milan, Italy. · Division of Early Drugs Development, European Institute of Oncology, 20141 Milan, Italy. · Palliative Care, Sassari, Italy. · Department of Medicine, European Institute of Oncology, 20141 Milan, Italy. · Division of Medical Senology, European Institute of Oncology, 20141 Milan, Italy. Electronic address: · Pubmed 28131905
  • Breast Cancer Program, Istituto Europeo di Oncologia, Milano, Italy. · Breast Oncology Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. · Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria. · Klinik St. Anna, Luzern, Switzerland. · German Breast Group, Neu-Isenburg, Germany. · Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. · Department of Medical Oncology, Institut Jules Bordet, UniversitÕ Libre de Bruxelles, Brussels, Belgium. · Tumor and Breast Center ZeTuP, St. Gallen. · Breast Center, Kantonsspital St. Gallen, St. Gallen, Switzerland. · Institut de Cancérologie Gustave Roussy, Villejuif, France. · Memorial Sloan Kettering Cancer Center, New York, USA. · Karolinska Institute and University Hospital, Stockholm, Sweden. · University of Bordeaux, Bordeaux, France. · Universitäts-Frauenklinik Tübingen, Tübingen, Germany. · Champalimaud Cancer Centre, Lisbon, Portugal. · Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA. · Hospital Universitario 12 de Octubre, Madrid, Spain. · Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. · Institut für Pathologie, Charité Universitätsmedizin Berlin, Berlin, Germany. · Azienda Usl Toscana Centro, Prato, Italy. · Rigshospitalet, Copenhagen, Denmark. · Peter McCallum Cancer Centre, Melbourne, Australia. · Marmara University School of Medicine, Istanbul, Turkey. · University of Toronto, Mount Sinai Hospital, Toronto, Canada. · University of Munich, München, Germany. · Comprehensive Cancer Center, University of Michigan, Ann-Arbor, USA. · National Taiwan University Hospital, Taipei, Taiwan. · University of Ulm, Ulm, Germany. · The National Cancer Institute, Cairo University, Cairo, Egypt. · Medical University of Gdansk, Gdansk, Poland. · Hospital Affiliated to Military Medical Science, Beijing, China. · Institute of Clinical Sciences, Sahlgrenska Academy, Sahlgrensky University Hospital, Gothenburg, Sweden. · Baylor College of Medicine, Houston, USA. · Institute of Oncology Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland. · Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Canada. · National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea. · Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. · LKH Salzburg, Paracelsus Medical University Clinics, Salzburg, Austria. · N.N. Petrov Research Institute of Oncology, St. Petersburg, Russian Federation. · Fudan University Cancer Hospital, Shanghai, China. · The Royal Marsden, Sutton, Surrey, UK. · Graduate School of Medicine Kyoto University, Sakyo-ku, Kyoto City, Japan. · Breast Cancer Now Research Centre, The Institute of Cancer Research, London, UK. · University of Milan, Milan. · Istituto Europeo di Oncologia, Milan, Italy. · Hamamatsu Oncology Center, Hamamatsu, Japan. · McMaster University, Hamilton, Canada. · National Cancer Center, Chaoyang District, Beijing, China. · Pubmed 28838210
  • Department of Surgery and Cancer, Imperial College London, London, UK. · Department of Experimental Oncology, European Institute of Oncology Milan, Italy. · Hematology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, IT. · Swammerdam Institute for Life Sciences, University of Amsterdam. · Genomics Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, Berkeley, CA, USA. · Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende (CS), Italy. · Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), and Institute for Stem Cell Technology and Experimental Medicine GmbH, Heidelberg, Germany. · Division of Pathology, European Institute of Oncology and University of Milan, School of Medicine, Milan, Italy. · Department of Oncology and Hemato-oncology, University of Milano, Milan, IT. · Division of Medical Senology, European Institute of Oncology, IEO, Milan, Italy. · Department of Biosciences, University of Milano, Milan, IT. · Pubmed 28112739
  • Division of Breast Surgery, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Breast Surgery, European Institute of Oncology, Milan, Italy. · Division of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy. · Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Milan, Italy. · Division of Pathology, European Institute of Oncology, Milan, Italy; University of Milan, School of Medicine, Milan, Italy. · Division of Breast Surgery, European Institute of Oncology, Milan, Italy; University of Milan, School of Medicine, Milan, Italy. · Pubmed 27810700
2016
  • IBCSG Central Pathology Laboratory, Department of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · University of Milan, Milan, Italy. · International Breast Cancer Study Group (IBCSG) Statistical Center, Boston, MA, USA. · Harvard T. H. Chan School of Public Health, Boston, MA, USA. · IBCSG Central Pathology Laboratory, Department of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · University of Milan, Milan, Italy. · Division of Experimental Therapeutics, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · National Institute of Oncology, Ráth György u. 7/9, Budapest, 1122, Hungary. · Breast Center St. Gallen, Kantonsspital, St. Gallen, Switzerland. · Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. · Divisione di Oncologia, Ospedale degli Infermi, Viale Settembrini 2, 47923, Rimini, Italy. · Program for Breast Health, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · International Breast Cancer Study Group, Translational Research Coordination and Central Pathology Office, IBCSG Coordinating Center, Effingerstrasse 40, 3008, Bern, Switzerland. · Frontier Science and Technology Research Foundation, Boston, MA, USA. · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. · Harvard Medical School, Boston, MA, USA. · Pubmed 27372069
  • University of Calgary, Alberta, Canada · Pfizer Inc., Collegeville, Pennsylvania, USA. · Pfizer Inc., New York, New York, USA. · University of Pennsylvania, Philadelphia, Pennsylvania, USA. · Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. · National Cancer Center, Goyang-si, Republic of Korea. · Istituto Europeo di Oncologia, Milan, Italy. · Aichi Cancer Center Hospital, Nagoya, Japan. · Brustzentrum der Universität München, Munich, Germany. · Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, Illinois, USA. · Pfizer Inc., San Diego, California, USA. · Pfizer Inc., Cambridge, Massachusetts, USA. · Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom. · University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA. · Pubmed 27368881
  • Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL, USA. Electronic address: · Institute of Cancer Research and Royal Marsden Hospital, London, UK. · Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital #4, Dnipropetrovsk, Ukraine. · National Cancer Center, Goyang-si, South Korea. · Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea. · NHO Osaka National Hospital, Osaka, Japan. · Istituto Europeo di Oncologia, Milan, Italy. · Center for Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA. · Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia. · Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. · Aichi Cancer Center Hospital, Nagoya, Japan. · Brustzentrum der Universität München (LMU), Munich, Germany. · Pfizer, San Diego, CA, USA. · Pfizer, Cambridge, MA, USA. · Pfizer, Collegeville, PA, USA. · Pfizer, New York, NY, USA. · University of California, Los Angeles, Los Angeles, CA, USA. · Pubmed 26947331
  • Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy. · International Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, 450 Brookline Avenue, Boston, MA, 02215, USA. · Institute of Oncology of Southern Switzerland (IOSI), Bellinzona, Switzerland. · International Breast Cancer Study Group, Bern, Switzerland. · Swiss Group for Clinical Cancer Research SAKK, Lugano Viganello, Switzerland. · IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA. · Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Via Ripamonti 435, Milan, 20141, Italy. · Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy. · International Breast Cancer Study Group (IBCSG) Coordinating Center, Effingerstrasse 40, Bern, CH-3008, Switzerland. · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy. · IBCSG Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA. · Dana-Farber Cancer Institute, Department of Biostatistics and Computatonal Biology, 450 Brookline Ave, Boston, MA, 02215, USA. · International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, Australia. · IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, 450 Brookline Avenue, Boston, MA, 02215, USA. · Program for Breast Health, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy. · Translational Research Coordination and Central Pathology Office, IBCSG Coordinating Center, Effingerstrasse 40, Bern, CH-3008, Switzerland. · Breast Unit of Southern Switzerland, Bellinzona, Switzerland. · National Cancer Institute of Canada, Kingston, ON, Canada. · Pubmed 27825388
  • Department of Oncology, Institute of Clinical Sciences, Sahgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: · Department of Mathematics and Statistics, University of Vermont, Burlington, Vermont. · International Breast Cancer Study Group Statistical Center, Frontier Science and Technology Research Foundation, Boston, Massachusetts. · International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Frontier Science and Technology Research Foundation, Harvard T. F. Chan School of Public Health, Boston, Massachusetts. · International Breast Cancer Study Group and University of Sydney, Sydney, Australia. · Senior Consultant Breast Cancer, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · International Breast Cancer Study Group, Bern, Switzerland. · Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · Institute of Radiotherapy, Klinik Hirslanden, Zürich, Switzerland. · Pubmed 27598802
  • Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan 20141, Italy. Electronic address: · Pubmed 26869050
  • Department of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy. · Department of Plastic and Reconstructive Surgery, European Institute of Oncology, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy. · Division of Radiotherapy, European Institute of Oncology, Milan, Italy. · Department of Surgery, European Institute of Oncology, Milan, Italy. · Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 26842491
  • Division of Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Division of Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Department of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy; University of Milan, School of Medicine, Milan, Italy. · Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 26746091
2015
  • Division of Medical Senology and International Breast Cancer Study Group, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 26241939
  • Division of Medical Senology, and International Breast Cancer Study Group, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy, · Pubmed 26177891
  • International Breast Cancer Study Group Coordinating Center and Bern University Hospital, Inselspital, Bern, Switzerland. Electronic address: · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA. · International Breast Cancer Study Group Coordinating Center, Bern, Switzerland. · Division of Medical Senology, European Institute of Oncology and International Breast Cancer Study Group, Milan, Italy. · Dana-Farber Cancer Institute and Alliance for Clinical Trials in Oncology, Boston, MA, USA. · Medical Oncology, Osp Papa Giovanni XXIII and International Breast Cancer Study Group, Bergamo, Italy. · Medical Oncology, Ospedale di Circolo and Fondazione Macchi, and International Breast Cancer Study Group, Varese, Italy. · Medical Oncology, Centro di Riferimento Oncologico, and International Breast Cancer Study Group, Aviano, Italy. · Breast Center, Kantonsspital St Gallen, Swiss Group for Clinical Cancer Research (SAKK), and International Breast Cancer Study Group, St Gallen, Switzerland. · Department of Oncology, University Hospital of Udine, University of Udine and International Breast Cancer Study Group, Udine, Italy. · Oncology Unit, Salvatore Maugeri Foundation, and International Breast Cancer Study Group, Pavia, Italy. · Surgical Oncology, Breast Services, Tata Memorial Hospital, and International Breast Cancer Study Group, Mumbai, India. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Institute of Oncology of Southern Switzerland, Swiss Group for Clinical Cancer Research, and International Breast Cancer Study Group, Lugano Viganello, Switzerland. · University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL, USA. · Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne and Australia and New Zealand Breast Cancer Trials Group, Newcastle, NSW, Australia, and International Breast Cancer Study Group. · International Breast Cancer Study Group Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA. · International Breast Cancer Study Group and University of Sydney, Sydney, NSW, Australia. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, Frontier Science and Technology Research Foundation, Boston, MA, USA. · Program for Breast Health (Senology), European Institute of Oncology, Milan, Italy; International Breast Cancer Study Group, Bern, Switzerland. · Tom Baker Cancer Centre and National Cancer Institute of Canada Clinical Trials Group, Calgary, AB, Canada. · Pubmed 26092816
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, and Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Department of Pathology, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine, Milan, Italy. · Department of Pathology, European Institute of Oncology, Milan, Italy. · University of Milan School of Medicine, Milan, Italy; Division of Senology, European Institute of Oncology, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Program of Senology (Breast Health), European Institute of Oncology, Milan, Italy. · Pubmed 25933934
  • Department of Biostatistics and Computational Biology, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Mailstop CLS-11007, Boston, MA, 02215, USA. · Institute of Oncology of Southern Switzerland, Swiss Group for Clinical Cancer Research (SAKK), Lugano Viganello, Switzerland. · Peter MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia. · Australia & New Zealand Breast Cancer Trials Group (ANZBCTG), University of Newcastle, Callaghan, NSW, Australia. · The University of Chicago Medical Center and Alliance for Clinical Trials in Oncology, Chicago, IL, USA. · Tom Baker Cancer Centre and NCIC Clinical Trials Group, Calgary, AB, Canada. · International Breast Cancer Study Group Coordinating Center and Central Pathology Office, Bern, Switzerland. · International Breast Cancer Study Group Central Pathology Office, Department of Pathology, European Institute of Oncology, Milan, Italy. · International Breast Cancer Study Group Central Pathology Office, Department of Pathology, European Institute of Oncology, Milan, Italy. · Pathological Department, National Institute of Oncology, Budapest, Hungary. · Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru. · Division of Pathology, Salvatore Maugeri Foundation, Pavia, Italy. · Struttura Operativa Complessa di Anatomia Patologica, Azienda Ospedaliero-Universitaria di Udine, Udine, Italy. · Kantonsspital St. Gallen, Swiss Group for Clinical Cancer Research (SAKK), St. Gallen, Switzerland. · University of Insubria-Ospedale di Circolo and Fondazione Macchi, Varese, Italy. · Department of Pathology, Vall d'Hebron University Hospital, SOLTI Group, Barcelona, Spain. · Pathology Department, Hospital Universitario «12 de Octubre», i+12, Universidad Complutense Madrid, SOLTI Group, Madrid, Spain. · Laboratoire Anatomopathologie, Institut Bergonié, Bordeaux, France. · EORTC, Brussels, Belgium. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Program for Breast Health, European Institute of Oncology, Milan, Italy. · International Breast Cancer Study Group Statistical Center, Frontier Science and Technology Research Foundation, Boston, MA, USA. · University of Sydney, Sydney, Australia. · International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. · Harvard T.H. Chan School of Public Health, Boston, MA, USA. · Frontier Science and Technology Research Foundation, Boston, MA, USA. · International Breast Cancer Study Group Central Pathology Office, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 26493064
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy · Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA. · Institute of Cancer Sciences, Glasgow University, Glasgow. · Southern General Hospital, Glasgow, UK. · Department of Pathology and Laboratory Medicine, IBCSG Central Pathology Laboratory, European Institute of Oncology, and University of Milan, Milan, Italy. · Breast Center, Kantonsspital, St Gallen Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. · Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark. · Department of Pathology, Institut Bergonié, Bordeaux. · Department of Pathology, Val d'Aurelle Cancer Institute, Montpellier, France. · Department of Pathology, Rigshospitalet, Copenhagen, Denmark. · International Breast Cancer Study Group (IBCSG) Statistical Center. · Department of Biostatistics and Computational Biology, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute, Boston, USA Harvard T.H. Chan School of Public Health, Harvard Medical School, Frontier Science and Technology Research Foundation, Boston, USA. · International Breast Cancer Study Group, Bern, Switzerland University of Sydney, Sydney, Australia. · Program of Breast Health, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 26387144
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Laboratory Medicine, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Department of Medicine, European Institute of Oncology, Milan, Italy. · Division of Pathology, European Institute of Oncology, Milan, Italy; School of Medicine, University of Milan, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Pubmed 26362840
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Department of Quantitative Methods and Statistics, University of Milan-Bicocca, Milan, Italy; Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Department of Pathology, European Institute of Oncology, Milan, Italy; School of Medicine, University of Milan, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Department of Pathology, European Institute of Oncology, Milan, Italy. · Program of Senology (Breast Health), European Institute of Oncology, Milan, Italy. · Pubmed 26255932
  • Division of Medical Senology, European Institute of Oncology, Milan · Department of Quantitative Methods and Statistics, University of Milan-Bicocca, Milan Division of Epidemiology and Biostatistics. · Department of Pathology, European Institute of Oncology, Milan School of Medicine, University of Milan, Milan. · Division of Epidemiology and Biostatistics. · Division of Medical Senology, European Institute of Oncology, Milan. · Division of Senology. · Department of Pathology, European Institute of Oncology, Milan. · Program of Senology (Breast Health), European Institute of Oncology, Milan, Italy. · Pubmed 25411418
2014
  • International Breast Cancer Study Group; European Institute of Oncology, Milan, Italy. · Pubmed 24516011
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 24998489
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Prevention and Genetics, European Institute of Oncology, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Scientific Direction, European Institute of Oncology, Milan, Italy. · Pubmed 24742826
  • Division of Pathology, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Pathology, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Pathology, European Institute of Oncology, Milan, Italy; University of Milan School of Medicine; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. Electronic address: · Pubmed 24709436
  • International Breast Cancer Study Group and Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. Electronic address: · International Breast Cancer Study Group and Breast Health Program, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 24360786
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, Unit of Biostatistics, Epidemiology and Public Health, University of Milan-Bicocca, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy; School of Medicine, University of Milan, Italy. · School of Medicine, University of Milan, Italy; Molecular Senology Unit, European Institute of Oncology, Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy. · Vice-Scientific Director, European Institute of Oncology, Milan, Italy. · Pubmed 24325948
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy; Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan, Italy. · Integrated Breast Surgery Unit, European Institute of Oncology and University of Milan, Italy. · Division of Senology, European Institute of Oncology, Milan, Italy. · Division of Radiation Oncology, European Institute of Oncology, Milan, Italy. · Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 24183613
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. Electronic address: · Division of Gynecologic Oncology, European Institute of Oncology, Milan, Italy. · Division of Diagnostic Radiology, European Institute of Oncology, Milan, Italy. · Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 24529906
2013
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Pubmed 24074780
  • Division of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 23633450
2012
  • Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22039080
  • Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 22987970
2011
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22015285
  • European Institute of Oncology, Milan, Italy. · Pubmed 21321298
2010
  • Research Unit, Medical Senology and International Breast Cancer Study Group, European Institute of Oncology, Milan, Italy. · Pubmed 20943602
  • Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 20471822
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Università degli Studi di Milano, Milan, Italy. · Pubmed 20458051
2009
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan, Italy. · Pubmed 19914533
  • Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 19468030
  • Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Milan, Italy. · Pubmed 19218304
2017
  • Signe Borgquist and Judy E. Garber, Dana-Farber Cancer Institute, Harvard Medical School; Anita Giobbie-Hurder, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute; Richard D. Gelber, IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, T.H. Chan Harvard School of Public Health, and Frontier Science and Technology Research Foundation; Karen N. Price, IBCSG Statistical Center and Frontier Science and Technology Research Foundation; Meredith M. Regan, IBCSG Statistical Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA; Signe Borgquist, Lund University, Lund, Sweden; Thomas P. Ahern, University of Vermont, Burlington, VT; Marco Colleoni and Aron Goldhirsch, IBCSG and European Institute of Oncology, Milan, Italy; István Láng, IBCSG and National Institute of Oncology, Budapest, Hungary; Marc Debled, Institut Bergonié, Bordeaux, France; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Roger von Moos, Cantonal Hospital Graubuenden, Chur; Swiss Group for Clinical Cancer Research and IBCSG; Manuela Rabaglio, IBCSG Coordinating Center and Inselspital, Bern; Beat Thürlimann, Breast Center St. Gallen, Kantonsspital, St. Gallen; Swiss Group for Clinical Cancer Research and IBCSG, Bern, Switzerland; Ian Smith, The Royal Marsden Hospital, London, United Kingdom; and Alan S. Coates, IBCSG and University of Sydney School of Public Health, Sydney, Australia. · Pubmed 28380313
  • Poornima Saha and Gini F. Fleming, The University of Chicago Medical Center, Chicago, IL; Meredith M. Regan, Weixiu Luo, Harold J. Burstein, and Richard D. Gelber, Dana-Farber Cancer Institute; Meredith M. Regan, Harold J. Burstein, and Richard D. Gelber, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello; Karin Ribi and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern, Switzerland; Prudence A. Francis, Peter MacCallum Cancer Center; St Vincent's Hospital; University of Melbourne, Melbourne; Josephine Stewart, Austin and Heidelberg Repatriation Medical Center, Heidelberg, Victoria; Prudence A. Francis, Josephine Stewart, and Michelle Nottage, University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, New South Wales; Michelle Nottage, Royal Brisbane Hospital, Brisbane, Queensland, Australia; Barbara A. Walley, University of Calgary; National Cancer Institute of Canada, Calgary, Alberta, Canada; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Vani Parmar, Tata Memorial Centre, Mumbai, India; Roberto Torres, Instituto Nacional del Cancer, Santiago de Chile, Chile; Meritxell Bellet, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona, Barcelona; Antonia Perelló, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Faysal Dane, Marmara University Hospital, Istanbul, Turkey; Antonio Moreira, Instituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugal; Daniel Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa; and Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy. · Pubmed 28654365
2016
  • Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania. · Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania. · Pubmed 27325862
  • Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H. Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria, Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland; Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven, Belgium; István Láng, National Institute of Oncology, Budapest, Hungary. · Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H. Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria, Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland; Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven, Belgium; István Láng, National Institute of Oncology, Budapest, Hungary. · Pubmed 27217455
  • Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru. · Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru. · Pubmed 27044936
  • Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland. · Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland. · Pubmed 26786933
2015
  • Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia. · Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia. · Pubmed 26215945
  • Division of Breast Surgery, European Institute of Oncology, Milan, Italy, · Pubmed 25515197
2014
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy, · Pubmed 25007961
2013
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy. · Pubmed 23915740
  • Department of Medicine, European Institute of Oncology, Milan, Italy. Electronic address: · Pubmed 23871531
  • Division of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Pubmed 23725877
  • Molecular Senology Unit, Senology Division, European Institute of Oncology, Milan, Italy. · Pubmed 23491275
  • Division of Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. Electronic address: · Pubmed 24091127
  • Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy. · Pubmed 23912960
  • Division of Pathology, European Institute of Oncology, Milan, Italy. · Pubmed 23763700
  • Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy. · Pubmed 23748238
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 23245877
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 23098574
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan 20141, Italy. · Pubmed 23022996
2012
  • European Institute of Oncology, Medical Oncology, Milan, Italy. · Pubmed 22827581
  • Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22520733
  • Medical Senology Research Unit & Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22749924
  • Division of Breast Surgery, European Institute of Oncology, Milan, Italy. · Pubmed 22618719
  • Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 22467243
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22399188
  • Medical Senology Research Unit, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 22341133
  • Division of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 22228432
  • Division of Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 22065291
  • Department of Medicine, Division of Medical Oncology, Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 21525402
  • Division of Senology, Unit of Molecular Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 21468637
2011
  • Division ofSenology, European Institute of Oncology, Milan, Italy. · Pubmed 22015302
  • Division of Senology, European Institute of Oncology, Milano, Italy. · Pubmed 21479691
  • International Breast Cancer Study Group Central Pathology Office, Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 21335417
  • Division of Breast Surgery, European Institute of Oncology, Milan, Italy. · Pubmed 22015303
  • Division of Medical Oncology, Department of Medicine, Unit Research of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 21822638
  • Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 21452022
  • Medical Senology Research Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 21397505
  • Division of Senology, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 21248632
  • Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, Milano, Italy. · Pubmed 21221766
  • Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435, Milan, Italy. · Pubmed 20638282
2010
  • Research Unit of Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 20304562
  • European Institute of Oncology, Medical Senology Research Unit, Division of Medical Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 20095792
  • Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 21147693
  • Division of Nuclear Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. · Pubmed 20533032
  • Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 20625816
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy. · Pubmed 20332136
  • Unit of Research in Medical Senology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 20117001
  • Division of Breast Surgery, European Institute of Oncology, Via Ripamonti 435, Milan, Italy. · Pubmed 19944605
  • Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 19633051
2009
  • Research Unit in Medical Senology, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 20044624
  • Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano, Italy. · Pubmed 19884553
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. · Pubmed 19562480
  • Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy. · Pubmed 19264824
  • Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy. · Pubmed 19182679
Miscellaneous cities in Italy
2015
  • Division of Medical Senology, European Institute of Oncology, Italy; International Breast Cancer Study Group, Italy. Electronic address: · Division of Medical Senology, European Institute of Oncology, Italy. · Pubmed 26249119
University of Milan Statale
2010
  • Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Università degli Studi di Milano, Milan, Italy. · Pubmed 20458051
2017
  • Signe Borgquist and Judy E. Garber, Dana-Farber Cancer Institute, Harvard Medical School; Anita Giobbie-Hurder, International Breast Cancer Study Group (IBCSG) Statistical Center, Dana-Farber Cancer Institute; Richard D. Gelber, IBCSG Statistical Center, Dana-Farber Cancer Institute, Harvard Medical School, T.H. Chan Harvard School of Public Health, and Frontier Science and Technology Research Foundation; Karen N. Price, IBCSG Statistical Center and Frontier Science and Technology Research Foundation; Meredith M. Regan, IBCSG Statistical Center, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA; Signe Borgquist, Lund University, Lund, Sweden; Thomas P. Ahern, University of Vermont, Burlington, VT; Marco Colleoni and Aron Goldhirsch, IBCSG and European Institute of Oncology, Milan, Italy; István Láng, IBCSG and National Institute of Oncology, Budapest, Hungary; Marc Debled, Institut Bergonié, Bordeaux, France; Bent Ejlertsen, Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Roger von Moos, Cantonal Hospital Graubuenden, Chur; Swiss Group for Clinical Cancer Research and IBCSG; Manuela Rabaglio, IBCSG Coordinating Center and Inselspital, Bern; Beat Thürlimann, Breast Center St. Gallen, Kantonsspital, St. Gallen; Swiss Group for Clinical Cancer Research and IBCSG, Bern, Switzerland; Ian Smith, The Royal Marsden Hospital, London, United Kingdom; and Alan S. Coates, IBCSG and University of Sydney School of Public Health, Sydney, Australia. · Pubmed 28380313
  • Poornima Saha and Gini F. Fleming, The University of Chicago Medical Center, Chicago, IL; Meredith M. Regan, Weixiu Luo, Harold J. Burstein, and Richard D. Gelber, Dana-Farber Cancer Institute; Meredith M. Regan, Harold J. Burstein, and Richard D. Gelber, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello; Karin Ribi and Jürg Bernhard, International Breast Cancer Study Group Coordinating Center; Jürg Bernhard, Bern University Hospital, Inselspital, Bern, Switzerland; Prudence A. Francis, Peter MacCallum Cancer Center; St Vincent's Hospital; University of Melbourne, Melbourne; Josephine Stewart, Austin and Heidelberg Repatriation Medical Center, Heidelberg, Victoria; Prudence A. Francis, Josephine Stewart, and Michelle Nottage, University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, New South Wales; Michelle Nottage, Royal Brisbane Hospital, Brisbane, Queensland, Australia; Barbara A. Walley, University of Calgary; National Cancer Institute of Canada, Calgary, Alberta, Canada; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Vani Parmar, Tata Memorial Centre, Mumbai, India; Roberto Torres, Instituto Nacional del Cancer, Santiago de Chile, Chile; Meritxell Bellet, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona, Barcelona; Antonia Perelló, Hospital Universitari Son Espases, Palma de Mallorca, Spain; Faysal Dane, Marmara University Hospital, Istanbul, Turkey; Antonio Moreira, Instituto Português de Oncologia Francisco Gentil - Centro de Lisboa, Lisbon, Portugal; Daniel Vorobiof, Sandton Oncology Centre, Johannesburg, South Africa; and Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy. · Pubmed 28654365
2016
  • Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania. · Marco Colleoni, Giuseppe Viale, and Aron Goldhirsch, European Institute of Oncology; Giuseppe Viale, University of Milan, Milan; Lorenzo Gianni, Ospedale degli Infermi, Rimini; Fabio Puglisi, University Hospital of Udine, University of Udine, Udine; Carlo Tondini, Osp. Papa Giovanni XXIII, Bergamo; Katia Cagossi, Ospedale di Carpi, Carpi, Italy; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, Meredith M. Regan, and Karen N. Price, International Breast Cancer Study Group Statistical Center; Kathryn P. Gray, Shari Gelber, Richard D. Gelber, and Meredith M. Regan, Dana-Farber Cancer Institute; Kathryn P. Gray and Richard D. Gelber, Harvard T.H. Chan School of Public Health; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Richard D. Gelber and Karen N. Price, Frontier Science and Technology Foundation, Boston, MA; István Láng, National Institute of Oncology, Budapest, Hungary; Beat Thürlimann, Kantonsspital, St Gallen; Beat Thürlimann, Elena Kralidis, and Daniel Rauch, Swiss Group for Clinical Cancer Research, Bern; Elena Kralidis, Kantonsspital Aarau, Aarau; Daniel Rauch, Spital Thun, Thun, Switzerland; Ehtesham A. Abdi, The Tweed Head Hospital, Tweed Heads, New South Wales and Griffith University, Southport, Queensland; Ehtesham A. Abdi and Jacquie Chirgwin, Australia and New Zealand Breast Cancer Trials Group; Jacquie Chirgwin, Box Hill and Maroondah Hospitals and Monash University, Melbourne, Victoria; Alan S. Coates, International Breast Cancer Study Group and University of Sydney School of Public Health, Sydney, New South Wales, Australia; Henry L. Gomez, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru; Barbro K. Linderholm, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden; and Alexandru Eniu, Cancer Institute Ion Chiricuta, Cluj, Romania. · Pubmed 27325862
  • Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H. Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria, Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland; Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven, Belgium; István Láng, National Institute of Oncology, Budapest, Hungary. · Jacquie H. Chirgwin and John F. Forbes, University of Newcastle; John F. Forbes, Calvary Mater Newcastle, Newcastle; Alan S. Coates, University of Sydney School of Public Health, Sydney, New South Wales; Jacquie H. Chirgwin, Box Hill Hospital; Jacquie H. Chirgwin, Maroondah Hospital; Jacquie H. Chirgwin, Monash University, Melbourne, Victoria, Australia; Anita Giobbie-Hurder, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center, Dana-Farber Cancer Institute; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard Medical School, Boston, MA; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergonié, Bordeaux, France; Aron Goldhirsch and Marco Colleoni, European Institute of Oncology, Milan, Italy; Ian Smith, The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom; Manuela Rabaglio, Inselspital, Bern; Beat Thürlimann, Kantonsspital, St. Gallen, Switzerland; Patrick Neven, University of Leuven; Patrick Neven, University Hospitals Leuven, Leuven, Belgium; István Láng, National Institute of Oncology, Budapest, Hungary. · Pubmed 27217455
  • Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru. · Meredith M. Regan and Richard D. Gelber, Dana-Farber Cancer Institute, Harvard Medical School; Karen N. Price and Richard D. Gelber, Frontier Science and Technology Research Foundation; Richard D. Gelber, Harvard T.H. Chan School of Public Health, Boston, MA; Prudence A. Francis, MacCallum Cancer Center, St Vincent's Hospital, University of Melbourne, Melbourne; University of Newcastle, Newcastle; Alan S. Coates, University of Sydney, Sydney, Australia; Olivia Pagani, Institute of Oncology of Southern Switzerland, Lugano Viganello, Switzerland; Gini F. Fleming, University of Chicago Medical Center, Chicago, IL; Barbara A. Walley, National Cancer Institute of Canada Clinical Trials Group, Calgary, Alberta, Canada; Giuseppe Viale, University of Milan; Giuseppe Viale, Marco Colleoni, and Aron Goldhirsch, European Institute of Oncology, Milan; Carlo Tondini, Ospedale Papa Giovanni XXIII, Bergamo; Graziella Pinotti, Ospedale di Circolo and Fondazione Macchi, Varese, Italy; István Láng, National Institute of Oncology, Budapest, Hungary; Henry L. Gómez, Instituto Nacional de Enfermedades Neoplásticas, Lima, Peru. · Pubmed 27044936
  • Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland. · Marco Colleoni and Aron Goldhirsch, European Institute of Oncology and International Breast Cancer Study Group, Milan; Lorenzo Gianni, Ospedale degli Infermi and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy; Zhuoxin Sun, Karen N. Price, and Richard D. Gelber, International Breast Cancer Study Group Statistical Center and Frontier Science and Technology Research Foundation; Zhuoxin Sun and Richard D. Gelber, Harvard T.F. Chan School of Public Health; Richard D. Gelber, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Per Karlsson, Institute of Selected Clinical Sciences, Sahlgrenska Academy, Sahlgrenska University Hospital, Gothenburg, Sweden; John F. Forbes, Australia and New Zealand Breast Cancer Trials Group, University of Newcastle, Newcastle Mater Hospital, Newcastle; Alan S. Coates, International Breast Cancer Study Group and University of Sydney, Sydney, New South Wales, Australia; Beat Thürlimann, Breast Center Kantonsspital, St Gallen, and Swiss Group for Clinical Cancer Research; and Monica Castiglione, International Breast Cancer Study Group, Bern, Switzerland. · Pubmed 26786933
2015
  • Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia. · Otto Metzger Filho, Anita Giobbie-Hurder, and Eric P. Winer, Dana-Farber Cancer Institute; Richard D. Gelber and Meredith M. Regan, Harvard Medical School; Karen N. Price, Frontier Science and Technology Research, Boston, MA; Elizabeth Mallon, Southern General Hospital; Barry Gusterson, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom; Giuseppe Viale, European Institute of Oncology and University of Milan; Marco Colleoni and Aron Goldhirsch, European Institute of Oncology, Milan, Italy; Beat Thürlimann, Kantonsspital, St. Gallen, and Swiss Group for Clinical Cancer Research, Bern, Switzerland; Bent Ejlertsen, Rigshospitalet, Copenhagen, Denmark; Marc Debled, Institut Bergoniié, Bordeaux, France; and Alan S. Coates, International Breast Cancer Study Group, Bern, Switzerland, and University of Sydney, Sydney, Australia. · Pubmed 26215945
2013
  • Division of Pathology, European Institute of Oncology, Milan, Italy. · Pubmed 23763700
2011
  • International Breast Cancer Study Group Central Pathology Office, Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 21335417
  • Division of Senology, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 21248632
2010
  • Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy. · Pubmed 19633051
40 Other Locations Show
Yearly article counts 09131412161615161100
 
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.